ABEONA THERAPEUTICS INC.

ABEO · Nasdaq · SIC 2834: Pharmaceutical Preparations
369
SEC Filings

Business Summary

Abeona Therapeutics Inc. is a commercial-stage biopharmaceutical company developing cell and gene therapies for life-threatening rare diseases. Its lead product, ZEVASKYN (prademagene zamikeracel), received FDA approval on April 28, 2025, as the first and only autologous cell-based gene therapy for wounds in recessive dystrophic epidermolysis bullosa (RDEB) patients. The company also develops AAV-based gene therapies for ophthalmic diseases using its novel AIM capsid technology, and operates a cGMP manufacturing facility in Cleveland, Ohio.

Next Earnings

Q2 FY2026 — expected 2026-08-11

Key Facts from Earnings Calls

TypeSubjectDetailQuarter
topic_mentionABEOdiscussed_in_filing Cybersecurity
topic_mentionABEOdiscussed_in_filing Trusted Computing
topic_mentionABEOdiscussed_in_filing Blockchain & Crypto
topic_mentionABEOdiscussed_in_filing Regulation
topic_mentionABEOdiscussed_in_filing Healthcare & Bio
topic_mentionABEOdiscussed_in_filing AI Compute
topic_mentionABEOdiscussed_in_filing Platform & Ecosystem
topic_mentionABEOdiscussed_in_filing Sovereign & Government
topic_mentionABEOdiscussed_in_filing Cybersecurity
topic_mentionABEOdiscussed_in_filing Trusted Computing
topic_mentionABEOdiscussed_in_filing Blockchain & Crypto
topic_mentionABEOdiscussed_in_filing Regulation
topic_mentionABEOdiscussed_in_filing Healthcare & Bio
topic_mentionABEOdiscussed_in_filing AI Compute
topic_mentionABEOdiscussed_in_filing Platform & Ecosystem
topic_mentionABEOdiscussed_in_filing Sovereign & Government
topic_mentionABEOdiscussed_in_filing Cybersecurity
topic_mentionABEOdiscussed_in_filing Trusted Computing
topic_mentionABEOdiscussed_in_filing Blockchain & Crypto
topic_mentionABEOdiscussed_in_filing Regulation

Annual Reports (10-K)

FiledPeriodAccessionSourceFull Text
2026-03-172025-12-310001493152-26-010413EDGAR79K words
2025-03-202024-12-310001493152-25-010978EDGAR—
2024-03-182023-12-310001493152-24-010190EDGAR—
2023-03-292022-12-310001493152-23-009381EDGAR—
2022-03-312021-12-310001493152-22-008259EDGAR—
2021-03-242020-12-310001493152-21-006705EDGAR—
2020-03-162019-12-310001493152-20-004015EDGAR—
2019-03-182018-12-310001144204-19-014623EDGAR—
2018-03-162017-12-310001144204-18-015277EDGAR—
2017-03-302016-12-310001144204-17-017709EDGAR—

Quarterly Reports (10-Q)

FiledPeriodAccessionSourceFull Text
2025-11-122025-09-300001493152-25-021723EDGAR30K words
2025-08-142025-06-300001641172-25-023716EDGAR—
2025-05-152025-03-310001641172-25-010516EDGAR—
2024-11-142024-09-300001493152-24-045340EDGAR—
2024-08-122024-06-300001493152-24-031150EDGAR—
2024-05-152024-03-310001493152-24-019459EDGAR—
2023-11-132023-09-300001493152-23-040323EDGAR—
2023-08-082023-06-300001493152-23-027104EDGAR—
2023-05-112023-03-310001493152-23-016278EDGAR—
2022-11-142022-09-300001493152-22-031655EDGAR—
2022-08-112022-06-300001493152-22-021969EDGAR—
2022-05-132022-03-310001493152-22-013174EDGAR—

Recent Current Reports (8-K)

FiledAccessionSourceFull Text
2026-03-200001493152-26-011863EDGAR1K words
2026-03-170001493152-26-010408EDGAR—
2026-03-090001493152-26-009299EDGAR—
2025-11-120001493152-25-021721EDGAR—
2025-08-140001641172-25-023715EDGAR—
2025-07-180001641172-25-020227EDGAR—
2025-07-020001641172-25-017460EDGAR—
2025-05-190001641172-25-011452EDGAR—
2025-05-150001641172-25-010514EDGAR—
2025-05-120001641172-25-009564EDGAR—

369 total filings indexed. 337 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR

Sector Peers

SXTP — 60 DEGREES PHARMACEUTICALS, INC. ABT — ABBOTT LABORATORIES ABVC — ABVC BIOPHARMA, INC. ACAD — ACADIA PHARMACEUTICALS INC ACTU — ACTUATE THERAPEUTICS, INC. ADCT — ADC Therapeutics SA ADIL — ADIAL PHARMACEUTICALS, INC. AEON — AEON Biopharma, Inc.

Tags

rare-genetic-diseases cell-and-gene-therapy ophthalmic-diseases dermatology-/-epidermolysis-bullosa current-good-manufacturing-practices-(cgmp) chemistry-manufacturing-and-controls-(cmc)

Company Identity

CIK0000318306
TickerABEO
ExchangeNasdaq
SIC2834: Pharmaceutical Preparations
IncorporatedDE
HeadquartersCleveland, Ohio

Get More Data

This is the free public profile. For structured JSON with full provenance chain, use the API:

JSON Profile Stock Quote AI Readiness Report
Origin Provenance
page leaf: 37e784b62f09ba4a690158c73f6e45795ba205399ca2e420b8f1b75d213ce437
parent: 5457554bc19e8d85bdfd12dcfa3e06e2bb31addbb5233a1e30d0337a5708059d
content hash: 7b808c695b7775f42f9db41a358df7f80ae7125bdb7ad567023119e30daf2dea
signed: 2026-04-13T04:43:24.968Z
sources: 22 verified data leaves
chain: SEC.gov PEM → origin.rootz.global extraction → this page
verify: sha256(content_hash + parent + timestamp) = leaf